Clinical Trial

Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 25, 2025 (before its estimated February 7, 2026 completion). Its status may not reflect the trial's current state.
Summary
Melasma is a localized, acquired hyperpigmentary skin disorder characterized by well-defined, light to dark brown patches. Based on clinical practice and extensive literature reports, tranexamic acid and reduced Glutathione (GSH) are both applied in the treatment of melasma, but their water-soluble nature presents challenges for transdermal absorption. Our preliminary basic and clinical research has demonstrated that ultrasound-assisted delivery significantly enhances the absorption of tranexamic acid and other water-soluble components. Its effect on the skin barrier is temporary and reversible. This study aims to evaluate the efficacy and safety of a compound solution (10% tranexamic acid, 2% GSH) delivered via ultrasound for melasma treatment through a split-face controlled trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-23.
Status change: Not Yet Recruiting → Recruiting 2025-11-24
Trial Details
NCT Number NCT07202156
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Melasma (Facial Melasma)
Enrollment 35 participants
Start Date 2024-10-20
Primary Completion 2026-02-07 (estimated)
Study Completion 2026-02-25 (estimated)
Updated on ClinicalTrials.gov 2025-11-25